VCNX · Vaccinex, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $601.0K | $570.0K | $275.0K | $900.0K | $50.0K | $523.0K |
| Cost of Revenue | - | - | - | - | $2.0K | $199.0K |
| Gross Profit | - | - | - | - | $48.0K | $324.0K |
| R&D | $12.54M | $16.57M | $13.98M | $17.16M | $21.55M | $25.67M |
| SG&A | $6.79M | $6.88M | $6.20M | $6.23M | $7.41M | $6.67M |
| Total Operating Expenses | $19.34M | $23.45M | $20.18M | $23.39M | $28.96M | $32.54M |
| D&A | $94.0K | $119.0K | $207.0K | $169.0K | $307.0K | $249.0K |
| Operating Income | ($18.73M) | ($22.89M) | ($19.91M) | ($22.49M) | ($28.33M) | ($32.02M) |
| Interest Expense | $2.0K | $1.0K | $2.0K | $809.0K | $489.0K | $308.0K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ($18.63M) | ($19.82M) | ($19.82M) | ($22.38M) | ($28.85M) | ($31.86M) |
| EPS - Basic | ($8.88) | ($43.68) | ($163.80) | - | - | - |
| EPS - Diluted | ($8.88) | ($43.68) | ($163.80) | - | - | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.11M | $1.53M | $6.39M | $8.59M | $10.60M | $2.78M |
| Accounts Receivable | $838.0K | $961.0K | $175.0K | - | $157.0K | $898.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.96M | $2.04M | $1.52M | $1.06M | $3.17M | $3.21M |
| Current Assets | $2.53M | $3.35M | $7.48M | $9.40M | $11.29M | $4.01M |
| Total Assets | $2.60M | $3.63M | $7.98M | $9.84M | $11.70M | $4.60M |
| Current Liabilities | $5.08M | $5.92M | $2.54M | $2.26M | $13.18M | - |
| Long-term Debt | $0 | $26.0K | $101.0K | $175.0K | $1.13M | - |
| Total Liabilities | $5.08M | $5.94M | $2.78M | $2.43M | $14.31M | $6.88M |
| Stockholders' Equity | ($2.49M) | ($2.31M) | $5.19M | $7.41M | ($26.57M) | ($26.24M) |
| Retained Earnings | ($358.56M) | ($339.93M) | ($319.68M) | ($299.86M) | ($277.48M) | ($248.63M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.19M) | ($17.23M) | ($19.07M) | ($25.30M) | ($28.65M) | ($30.71M) |
| Investing Cash Flow | ($22.0K) | ($67.0K) | ($99.0K) | ($32.0K) | ($290.0K) | $14.07M |
| Financing Cash Flow | $15.78M | $12.45M | $16.98M | $23.32M | $36.76M | $13.80M |
| CapEx | $22.0K | $67.0K | $99.0K | $32.0K | $290.0K | $78.0K |
| Free Cash Flow | ($16.21M) | ($17.30M) | ($19.17M) | ($25.33M) | ($28.94M) | ($30.79M) |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | 96.0% | 62.0% |
| Operating margin | -3117.3% | -4014.9% | -7238.5% | -2498.9% | -56662.0% | -6121.4% |
| EBITDA margin | -3101.7% | -3994.0% | -7163.3% | -2480.1% | -56048.0% | -6073.8% |
| Net margin | -3100.5% | -3476.3% | -7205.5% | -2486.7% | -57702.0% | -6092.4% |
| Free cash flow margin | -2696.8% | -3035.3% | -6972.0% | -2814.4% | -57874.0% | -5887.8% |
| FCF / Net income | 0.87 | 0.87 | 0.97 | 1.13 | 1.00 | 0.97 |
| R&D / Revenue | 2087.4% | 2907.7% | 5083.3% | 1906.7% | 43098.0% | 4908.2% |
| SG&A / Revenue | 1130.0% | 1207.2% | 2255.3% | 692.2% | 14810.0% | 1275.1% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -717.8% | -545.7% | -248.4% | -227.4% | -246.5% | -692.1% |
| Return on equity | 749.0% | 857.4% | -381.6% | -301.9% | 108.6% | 121.4% |
| Return on invested capital | - | - | -297.0% | -234.2% | - | - |
| Liquidity | ||||||
| Current ratio | 0.50 | 0.57 | 2.95 | 4.17 | 0.86 | - |
| Quick ratio | 0.50 | 0.57 | 2.95 | 4.17 | 0.86 | - |
| Cash ratio | 0.22 | 0.26 | 2.52 | 3.81 | 0.80 | - |
| Leverage | ||||||
| Debt / Equity | 0.00 | -0.01 | 0.02 | 0.02 | -0.04 | - |
| Debt / Assets | 0.00 | 0.01 | 0.01 | 0.02 | 0.10 | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -9367.5x | -22885.0x | -9953.0x | -27.8x | -57.9x | -103.9x |
| Equity multiplier | -1.04 | -1.57 | 1.54 | 1.33 | -0.44 | -0.18 |
| Liabilities / Assets | 1.96 | 1.64 | 0.35 | 0.25 | 1.22 | 1.49 |
| Efficiency | ||||||
| Asset turnover | 0.23 | 0.16 | 0.03 | 0.09 | 0.00 | 0.11 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 509d | 615d | 232d | - | 1146d | 627d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | 578343d | 5884d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | 746.6x | - | - | - |
| P / S | 3.4x | 7.5x | 14099.4x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 5.4% | 107.3% | -69.4% | 1700.0% | -90.4% | 481.1% |
| Revenue CAGR (3y) | -12.6% | 125.1% | -19.3% | 115.4% | - | - |
| Revenue CAGR (5y) | 2.8% | 44.7% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | -85.2% | - |
| Operating income growth (YoY) | 18.1% | -15.0% | 11.5% | 20.6% | 11.5% | -51.7% |
| Net income growth (YoY) | 6.0% | 0.0% | 11.5% | 22.4% | 9.5% | -70.2% |
| EPS growth (YoY) | 79.7% | 73.3% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 6.3% | 9.8% | 24.3% | 12.5% | 6.0% | -42.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -7.7% | - | -29.9% | - | -1.3% | -204.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$500.0K totalExclusive Product License$500.0K · 100.0%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
-140.09
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing VACCINEX against the 5 most active filers in the same SIC group.